Hannah Clarke

In this installment, sisters Amy Pearlman, MD, and Michelle Pearlman, MD, highlight Prime Institute, the practice they co-founded in South Florida.

"Despite prevalent OAB symptoms, only 6% of all LUTS prescriptions in men were for OAB medications," says Sarah Neu, MD, MSd, FRCSC.

The phase 3 ATLAS and ENVISION trials are exploring UGN-102 for intravesical solution in patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.

"The thing that's unique about this course, in my opinion, is that we are combining the vaginoplasty and phalloplasty discussions," says Kirtishri Mishra, MD.

In total, 73% of patients showed an increase in 24-hour urine volume from baseline to the end of the 1-month trial period.

In total, 77.8% of Black respondents, 72.7% of Asian respondents, 57.1% of Latino respondents, and 46.5% of White respondents indicated that the racial and ethnic diversity of residents at a program influenced their decision to preference signal or sub-internship with that program.

The UroActive device is currently being studied in the SOPHIA study, which published initial results earlier this year.

Dr. Vince has an interest in disparities in urologic care, specifically among patients with prostate cancer.

"Extra support from trusted peers can help make navigating complex health care systems easier for transgender patients, who often have to wait years before receiving gender-affirming genital surgery—while also managing the stress and trauma associated with being part of a society that often doesn’t accept non-conforming gender expression,” says Geolani Dy, MD, FACS

ARX517 is currently being studied in the phase 1/2 open-label APEX-01 trial.

Data among patients with follow-up of greater than 48 months demonstrated an IPSS reduction of 45.2% from baseline to 79 months following treatment.

"We are hoping this is something that we can repurpose quickly for those affected by these variants,” says Heather Christofk, PhD.

The rule includes a proposed unadjusted national average payment rate of US$21,376.53 for the device in 2024.

"The beauty is, now we can deliver a cisplatin-based chemotherapeutic orally, which is usually never done. And by targeting the prostate, we can reduce kidney and liver toxicity and the risk of peripheral neuropathy," says Shanta Dhar, PhD.

The prospective cohort study seeks to enroll 200 patients from the South Florida region and 1800 patients from international sites.

Urologists and other medical professionals can begin using the code on January 1, 2024 to facilitate the reimbursement of Li-ESWT involving the corpus cavernosum.

“Implementing Jelmyto earlier in real-world scenarios for LG-UTUC may offer appropriate low-risk patients the choice of minimal ablation or biopsy alone for renal preservation," says Hristos Z. Kaimakliotis, MD.

"We did an additional study where we surveyed all of the medical students who applied to urology this year... 1 in 5 applicants took programs off their list because they were located in states where abortion is illegal," says Chloe E. Peters, MD.

Data showed a decrease in patient symptoms following Aquablation procedures, with an average IPSS of 22.6 at baseline compared with 6.8 at 5-year follow-up.

"One of the things that made a difference, at least in my practice, was one of the newer pulse modulated holmium lasers," says Smita De, MD, PhD.

"Our most significant finding may be that patients experience financial toxicity despite their ability to remain compliant with treatment," says Daniel D. Joyce, MD.

"The fact that we are able to swab and look at these proteins means that we might be able to identify women at risk early on,” says Maria Florian-Rodriguez, MD.

A group of patients were shown to have an average of 6.3 cystitis episodes per year before administration of Lactobacillus, compared with 2.4 episodes after administration.

The study will assess the ability of Cu-64 SAR-bisPSMA to detect prostate cancer within the pelvic lymph nodes.

"Another thing is to customize your EHR with favorite orders and grouped orders, and these things can be standardized across a practice," says Sarah Hecht, MD.

"The high reproducibility of reader results across all regions is clinically valuable, with the potential to influence patient management prior to surgery for patients with newly diagnosed disease," says Phillip H. Kuo, MD, PhD.

"Personalized dosing allowed one-third of the men in this study to have treatment breaks while still achieving the same progression-free and overall survival outcomes they would have if they received continuous treatment," says Andrew Nguyen, MBBS, FRACP, AANMS.

The new space includes a clinical laboratory for IsoPSA testing, labs for research and development, offices, and manufacturing spaces for production and distribution of in vitro diagnostic kits.

Investigators assessed integration of mGPS for risk stratification based on data from the phase 3 IMmotion151 study and the phase 2 IMmotion150 study.

"About 29% of our high-risk patients tested AI biomarker negative, and they could thus be spared the long-term [adverse] effects of ADT for 2 to 3 years," says Andrew J. Armstrong, MD, MSc.